CryoLife says FDA approves new HeRO graft
ATLANTA -- CryoLife Inc. said Thursday that the Food and Drug Administration cleared a new version of its HeRO graft.
HeRO is used in patients with end-stage kidney disease who are on dialysis and have blocked central veins. The graft bypasses central veins to get blood to flow from a target artery to the heart. CryoLife said the new version of the graft has an adaptor that allows physicians to combine the HeRO with other dialysis access grafts.
CryoLife expects to start selling the device during the fourth quarter. The HeRO graft was first approved in the U.S. in 2008 and in Europe in 2011.
Shares of CryoLife rose 19 cents, or 3.2 percent, to $6.06 in afternoon trading.
ATLANTA-- CryoLife Inc. said Thursday that the Food and Drug Administration cleared a new version of its HeRO graft. CryoLife said the new version of the graft has an adaptor that allows physicians to combine the HeRO with other dialysis access grafts. Shares of CryoLife rose 19 cents, or 3.2 percent, to $6.06 in afternoon trading.